Expert Point of View: Guido Reifenberger, MD


Get Permission


I was impressed by this first study of dabrafenib in pediatric patients with BRAF V600E–mutated relapsed, refractory low-grade glioma.
— Guido Reifenberger, MD

Tweet this quote

“Low-grade gliomas are biologically and clinically heterogeneous entities with different genetic drivers,” said formal discussant of this trial, Guido Reifenberger, MD, of Heinrich Heine University, Düsseldorf, ­Germany.

“The BRAF V600 mutation is a novel therapeutic target in gliomas occurring in a subset of tumors. Anecdotal evidence and case reports suggest that BRAF inhibitors that target the V600E mutation are effective. I was impressed by this first study of dabrafenib in pediatric patients with BRAF V600E–mutated relapsed, refractory low-grade glioma,” Dr. Reifenberger told listeners.

“This was only a one-arm study, but these are promising data from the first prospective study of dabrafenib in this subgroup of pediatric patients,” he said. ■

Disclosure: Dr. Reifenberger has received research grants from Roche and Merck.


Related Articles

Preliminary Data Indicate Potential Role for Dabrafenib as Part of Therapy for Pediatric Low-Grade Gliomas With BRAF V600 Mutation

About 10% of children with low-grade gliomas have the BRAF V600E mutation, and preliminary studies suggest that the BRAF inhibitor dabrafenib (Tafinlar) may play an important role in treating this group of patients. A phase I/II trial presented at the 2016 European Society for Medical Oncology...

Advertisement

Advertisement



;
Advertisement

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.